A 47-year-old male patient in whom atrial septal defect (ASD) had been diagnosed 15 years previously was admitted for cardiac catheterization. He had definite cyanotic lips and nail beds and severe pulmonary arterial hypertension (PAH). He had received medical treatment only for the last few years after being diagnosed with Eisenmenger syndrome. After cardiac catheterization, he received iloprost inhalation therapy pre and postoperation and was discharged after successful surgical closure of the ASD. (Korean J Pediatr 2010;53:93-96) 
Introduction
Congenital Heart Disease (CHD) with pulmonary arterial hypertension (PAH) has high risk of postoperative morbidity and mortality. Iloprost (Ventavis ® inhalant, Bayer
Schering Pharma AG, German) is a chemically stable prostacyclin analogue with has potent pulmonary vasodilatation, anti-thrombotic, anti-inflammatory, and anti fibrotic effects 1, 2) . The inhaled iloprost has been approved to be effective in the treatment of PAH. We report a case of successful closure of ASD with severe PAH who was considered inoperable after using of inhaled iloprost.
Case report
A 47-year-old male patient was referred to the Pedi- 
Discussion
The ASD is one of the most common congenital heart diseases. Patients with long-standing ASD, clinical deterioration, such as PAH and arrhythmic complications tend to worsen over time 3, 4) . The survival depends on whether pulmonary hypertension develops during adulthood or not.
The most cause of death in ASD patients is right ventricular heart failure and arrhythmia 5) .
Pulmonary arterial hypertension frequently complicates the postoperative management of patients after congenital cardiac surgery 6, 7) . Especially, post-operative pulmonary hypertensive crisis is especially life threatening, which makes vasodilators, NO gas, muscle relaxant and Extracorporeal Membrane Oxygenation are treatment options 8, 9) .
The iloprost-a potent pulmonary vasodilator-directly act to lungs, so it is very effective in improvement of ventilation-perfusion mismatching and shunting flow 10) , pulmonary circulation, and gas exchange. In addition, it stabilizes the stretch induced surfactant production of type II alveolar cells and has potent anti-inflammatory effects 1, 2) . Therefore, inhaled iloprost has been approved to be effective in the treatment of PAH.
Recently, several authors reported operation after vasodilative therapy in CHD with PAH, who were considered inoperable [11] [12] [13] . They used the oral bosentan or intravenous prostacyclin for several months preoperatively.
Our patient is a similar case, but we used inhaled Iloprost instead. Iloprost shows superiority to the other products in that it is worth acting and a potent pulmonary vasodilator. The treatment period is relatively short and there is no need for intravenous delivery system and side effects of oral bosentan, such as elevated liver enzyme, can be avoided. Our patient showed transient hypotension and decreased O2 saturation during mechanical ventilation, but he recovered rapidly after infusion of inotropic agents and sedatives. In general, CHD with irreversibly obstructed pulmonary vasculature (Eisenmenger syndrome) is contraindicated for operation, but if there is some reversibility of the pulmonary vasculature, the use of inhaled iloprost may be very effective. Kim DK et al 14) reported liver transplantation of a patient with portopulmonary hypertension after "conditioning" therapy with iloprost and sildenafil.
Winterhalther M et al 15) reported that inhaled iloprost was effective in reducing PAH during cardiac surgery, immediately after weaning from cardiopulmonary bypass.
It is not easy to decide whether a patient, who has had a long-standing left to right shunt lesion and pulmonary hypertension, retains reversibility of pulmonary vasculature or not. Even though a thorough review of clinical manifestations, echocardiography, and cardiac catheterization is suggested as standard evaluation 16, 17) , a definite boundary is still obscure. In our case, it was reasonable for the patient to receive only medical treatment for few years, considering how he showed cyanosis and clubbing of fingers, and showing only scanty change of shunt ratio and pulmonary resistance during cardiac catheterization, leading the medical staff to believe he had Eisengmenger syndrome.
We take notice of the fact that pulmonary vascular disease may continue to progress even after the abolishment of left to right shunt, and that prolonged pulmonary vasodilator therapy may be required in patient with significant residual PAH, but we believe that elimination of hemody- 
